These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Psoriasis vulgaris exacerbated by imatinib therapy in chronic myelogenous leukemia].
    Author: Shimizu K, Kuroda H, Kida M, Watanabe H, Shirao S, Akiyama T, Fujimi A, Tanaka I, Sato T, Matsunaga T, Niitsu Y.
    Journal: Rinsho Ketsueki; 2005 Oct; 46(10):1152-5. PubMed ID: 16440780.
    Abstract:
    Administration of imatinib exacerbated psoriasis vulgaris in a case of chronic myelogenous leukemia (CML). After the cessation of imatinib therapy, the psoriasis was alleviated. Upon readministration of imatinib, the psoriasis worsened despite the improvement of hematological and cytogenetic findings in the CML. Psoriasis is known to be an autoimmune skin disease characterized by Th1 cell-mediated hyperproliferation of keratinocytes, and the type 1 helper T (Th1) cell subset increased with imatinib therapy. Thus, the exacerbation of psoriasis was likely due to the increase in Th1 cells associated with imatinib therapy.
    [Abstract] [Full Text] [Related] [New Search]